Ocugen (OCGN) has completed enrollment in its Phase 3 liMeliGhT trial for OCU400 in retinitis pigmentosa, a key clinical milestone that sits alongside fresh financial results and an auditor flagged going concern risk.

The completion of Phase 3 enrollment and the fresh financial disclosures arrive after a sharp move in Ocugen’s shares, with a 1 day share price return of 29.94% and a 30 day share price return of 66.67%. This has contributed to a 1 year total shareholder return of roughly 3x, although the 5 year total shareholder return remains deeply negative, suggesting recent momentum is building off a much lower base.

If this kind of high risk biotech story has your attention, you may also want to see how other health focused names stack up using our screener of 34 healthcare AI stocks as a starting point.

So with Ocugen’s shares already up sharply this year, is the current price still overlooking the risks flagged in its latest 10 K and ongoing losses, or are markets already accounting for most of the potential future growth?

Most Popular Narrative: 78% Undervalued

Ocugen’s most followed valuation narrative puts fair value at about $10.36 per share compared with the recent $2.30 close, framing the current move as only part of a much bigger story built around its late stage gene therapy programs and updated financial modelling.

The company’s modifier gene therapy platform leverages broad, gene agnostic mechanisms, potentially offering first/best in class, single treatment solutions for diseases like RP, Stargardt, and dry AMD. This positioning could allow Ocugen to benefit from ongoing advancements in biotechnology and genomics, as well as higher pricing and reimbursement for innovative, long acting therapies, which would positively impact long term net margins.

Want to see what is behind that double digit fair value estimate and steep discount rate assumptions? The narrative leans heavily on rapid revenue expansion, a swing from losses to profitability, and a future earnings multiple more often associated with mature sector leaders. Curious which projections have to line up for that story to hold together and how much growth is baked into those cash flow forecasts? The full breakdown connects each clinical milestone to a specific financial step in that valuation path.

Result: Fair Value of $10.36 (UNDERVALUED)

However, this depends on Ocugen funding its cash burn beyond a runway that only reaches early 2026 and avoiding setbacks across its small group of late stage programs.

Next Steps

Given that the story here mixes genuine upside potential with clear red flags, it makes sense to move quickly and look at the underlying data yourself. To see how those competing forces stack up side by side, take a look at the 2 key rewards and 3 important warning signs and decide where you stand.

Looking for more investment ideas?

If Ocugen has you thinking bigger about your portfolio, do not stop here, there are plenty of other potential opportunities worth lining up and comparing on your screen.

• Target possible bargains by scanning companies trading below their estimated worth using our 50 high quality undervalued stocks and see which names stand out on your radar.
• Strengthen your income stream by checking out businesses in the 14 dividend fortresses that focus on higher yields and consistent shareholder payouts.
• Prioritise resilience by reviewing companies in the 67 resilient stocks with low risk scores that pair steadier risk profiles with fundamentals you can scrutinise in detail.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.